Anatara Lifesciences Ltd

ASX:ANR ISIN:AU000000ANR0

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Following the successful licencing of our first product to leading global animal health company, Zoetis Inc, we are now focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.

     

Latest Headlines

Anatara Life Sciences (ASX:ANR) Investor Presentations Sydney and Melbourne

🕔2/11/2019 1:13:00 PM

This month, Anatara's CEO, Steve Lydeamore will be presenting to investors at events in Sydney and Melbourne. We would like to extend to you the invitation to attend.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Successful proof of concept studies

🕔2/7/2019 11:23:57 AM

Anatara Lifesciences Ltd (ASX:ANR) is pleased to report positive efficacy data from its in vitro Proof of Concept studies of its Gastrointestinal ReProgramming product. GaRP is a unique natural dietary supplement designed to restore and maintain a healthy human gut and microbiome.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Quarterly Report

🕔1/30/2019 11:03:48 AM

Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st December 2018. The Company's cash position at the end of the quarter stood at $1.5m. The Company also had $4,500,000 in deposits with terms of greater than 90 days. Expenditure during the quarter was in line with forecast.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Non-Executive Director Appointment

🕔1/23/2019 8:21:56 AM

Anatara Lifesciences (ASX:ANR) is pleased to announce the appointment of Dr. David Brookes as Non-Executive Director and Chair of the Audit and Risk Committee, effective from 23 January 2019.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) PAC Partners Equity Research Report

🕔1/15/2019 12:31:24 PM

PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a BUY rating and a 12-month price target of $1.40 per share.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Receives $1.249m R&D Tax Refund

🕔1/14/2019 8:39:28 AM

Anatara Lifesciences (ASX:ANR) is pleased to announce that it has received $1,249,299 from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive scheme.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Chairman's Address to Shareholders

🕔11/14/2018 10:20:11 AM

Anatara Lifesciences Ltd (ASX:ANR) provides the Company's Chairman Address to Shareholders.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Chief Executive Officer Appointment

🕔11/14/2018 8:23:04 AM

Anatara Lifesciences (ASX:ANR) is pleased to announce that it has appointed Mr Steven Lydeamore as Chief Executive Officer, effective as of 3rd December 2018.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Quarterly Report

🕔10/31/2018 10:01:44 AM

Anatara Lifesciences (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 30th September 2018. The Company's cash position at the end of the quarter stood at $7.1m.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) APVMA Approval for Detach

🕔10/29/2018 9:16:27 AM

Anatara Lifesciences (ASX:ANR) is pleased to announce that the Australian Pesticides and Veterinary Medicines Authority has registered Detach(R) with the approved label, "To aid in the control of scour and has positive health benefits in weaned piglets from 3 weeks of age and help increase survivability of scouring pre-weaning piglets".

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Formation of Product Development Advisory Board

🕔10/23/2018 2:39:28 PM

Anatara Lifesciences (ASX:ANR), a company focused on commercialising innovative products for gut health, is pleased to announce the formation of its Product Development Advisory Board. The Advisory Board consists of five key external experts: Dr Rebecca Burgell, Dr Jakob Begun, Prof Barry Campbell, Assoc Prof Simon Keely and Prof Peter Gibson, who will serve as the Chairman.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) 2018 Annual Report

🕔10/9/2018 8:31:26 AM

Anatara Lifesciences (ASX:ANR) is pleased to release its Annual Report, for the year ended 30th June 2018.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) CEO, Dr Mel Bridges Announces Retirement

🕔5/17/2018 8:30:21 AM

Anatara Lifesciences Ltd (ASX:ANR) announces that Executive Chairman, Dr Mel Bridges has informed the Board of his wish to retire from his role at Anatara with immediate effect and the Board has formally accepted his resignation.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Investor Presentation on Zoetis Exclusive Global License

🕔5/16/2018 1:39:11 PM

Anatara Lifesciences (ASX:ANR) is pleased to release a new investor presentation following the announcement that Anatara had established an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach(R).

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Exclusive Global License Agreement with Zoetis

🕔5/15/2018 9:50:29 AM

Anatara Lifesciences (ASX:ANR) is delighted to announce an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach(R) as a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour) in livestock and in horses.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Quarterly Report

🕔4/19/2018 8:27:06 AM

Anatara Lifesciences (ASX:ANR) today released its Appendix 4C financial report for the quarter ending 31st March 2018.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Half Yearly Report

🕔2/22/2018 9:13:31 AM

Anatara Lifesciences (ASX:ANR) today released its Appendix 4D financial report for the half year ending 31st December 2017.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Achieves a Major US FDA Milestone in the Registration of Detach(R) with Approval of the Human Food Safety Dossier

🕔2/5/2018 8:29:16 AM

Anatara Lifesciences (ASX:ANR) has achieved a significant milestone in the United States of America after receiving a "complete" letter from the US Food and Drug Administration for the Technical Section of its Human Food Safety submission. The HFS is a major component of a New Animal Drug Application which is currently underway and is necessary for enabling the marketing of Detach(R) in the US.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Receives $1.23m R&D Tax Refund

🕔1/18/2018 9:38:13 AM

Anatara Lifesciences (ASX:ANR) is pleased to announce that it has received $1,230,329 from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive scheme.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Presents at Australasian Pig Science Association Conference

🕔11/21/2017 3:38:26 PM

At the Australasian Pig Science Association Conference in Melbourne this week, Dr Trish Holyoake & Dr Tracey Mynott presented a poster highlighting the comparable efficacy of a single dose of Anatara's (ASX:ANR) Detach(R) product to in-feed Zinc oxide in reducing diarrhoea and antibiotic treatments in post-weaning piglets.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Chairman's Address to Shareholders

🕔11/13/2017 11:44:04 AM

Anatara Lifesciences Ltd (ASX:ANR) provides the Chairman's address to shareholders.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Dr Tracey Mynott Presents at TRI Science Business Inspiration Series

🕔11/3/2017 12:11:11 PM

Anatara Lifesciences (ASX:ANR) CSO, Dr Tracey Mynott, was recently invited to present at the Translational Research Institute's Science Business Inspiration Series. The series was launched with Session 1 "The whole journey: from idea to reality".

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Investor Presentation

🕔10/18/2017 8:24:01 AM

Anatara Lifesciences (ASX:ANR) is pleased to release its latest institutional roadshow presentation and market update that will be delivered to investors this week by CEO & Chairman, Dr Mel Bridges and Co-Founder and Chief Scientific Officer, Dr Tracey Mynott.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Annual Report 2017 Update

🕔10/4/2017 1:02:46 PM

Anatara Lifesciences Ltd (ASX:ANR) provides the Company's Annual Report 2017 Update.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Pork CRC Options Extended by 12 Months

🕔9/13/2017 9:36:01 AM

Anatara Lifesciences Limited (ASX:ANR) has today undertaken to extend by 12 months the expiry date of 250,000 Options which Anatara issued to the Pork Cooperative Research Centre in 2015.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) and Zoetis to Negotiate Terms of International Detach(R) Commercial Agreement

🕔8/21/2017 8:55:23 AM

Anatara Lifesciences Ltd (ASX:ANR) is pleased to announce that global animal health company, Zoetis Inc. has exercised its option to negotiate a commercial agreement for the worldwide development, distribution and marketing of Detach(R), with terms to be agreed.

Read Full Article

FINANCE VIDEO: Anatara Lifesciences Ltd (ASX:ANR) Gold Coast Investment Showcase Investor Presentation

🕔6/21/2017 2:07:56 PM

Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation for the Gold Coast Investment Showcase (June 21st & 22nd 2017).

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Wilsons Equity Research Report Issued with Buy Rating

🕔6/8/2017 10:30:52 AM

Wilsons maintain a BUY rating and $1.66 price target. Anatara's recent stock underperformance has simply reflected a slow quarter for news in the lead-up to a significant inflection point in the 2H.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Investor Update and R&D Tax Rebate

🕔6/6/2017 8:24:57 AM

Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide investors with an update on recent progress.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) ABC Video Program - Non-Antibiotic Treatment for Pigs

🕔3/23/2017 6:45:01 PM

An oral drench to protect piglets from gut infection could soon be available to pig farmers. It's been developed by scientists and is made from pineapples - taking antibiotics out of the food chain.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Half Yearly Report and Accounts

🕔2/23/2017 9:20:20 AM

Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide the Company's Half Yearly Report for the period ended 31 December, 2016.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Receives Second Payment for Detach Under The Agreement with Zoetis (NYSE:ZTS)

🕔1/30/2017 10:20:19 AM

Anatara Lifesciences Ltd (ASX:ANR) is pleased to announce that it has received a second payment under the exclusive Evaluation and License Option Agreement with the leading global animal health company Zoetis Inc. (NYSE:ZTS) for Detach(TM), Anatara's non-antibiotic anti-infective product.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Research Report 'A Good Gut Feeling' by NDF Research

🕔1/25/2017 10:24:29 AM

NDF Research yesterday released its initiation report on Anatara Lifesciences Ltd (ASX:ANR). The report provided a valuation at $2.22 per share base case and $5.94 per share optimistic case using a DCF approach, with a target price of $4.00 per share sitting midpoint of their valuation range.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Investor Update

🕔11/22/2016 8:27:13 AM

Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its updated investor presentation.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) AGM Presentation

🕔11/15/2016 11:51:40 AM

Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide the company's AGM Presentation held on 15 November 2016.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Chairman's Address to Shareholders

🕔11/15/2016 11:50:40 AM

Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide the company's latest Chairman's Address to Shareholders at 2016 AGM.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Annual Report to Shareholders

🕔10/14/2016 11:17:04 AM

Anatara Lifesciences Ltd (ASX:ANR) directors present their report on the consolidated entity consisting of Anatara Lifesciences Ltd and the entities it controlled at the end of, or during, the year ended 30 June 2016.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Receives R&D Tax Refund

🕔10/14/2016 8:30:42 AM

Anatara Lifesciences Ltd (ASX:ANR) is pleased to announce that it has received $420,460 from the Australian Tax Office for the Research and Development (R&D) Tax Incentive. This refund is from Anatara's 2014-15 research activities and future refunds will increase significantly. The company is in the process of finalising its 2015-16 tax claim.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Investor Presentation

🕔10/13/2016 8:25:28 AM

Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its latest institutional roadshow presentation and market update that will be delivered to investors over the next two weeks by CEO & Chairman, Dr Mel Bridges and Co-Founder and Chief Scientific Officer, Dr Tracey Mynott.

Read Full Article

Anatara Lifesciences Limited's (ASX:ANR) Antibiotic Alternative Edges Closer to Commercialisation as UN Declares Drug Resistance 'The Greatest and Most Urgent global risk'

🕔10/4/2016 8:30:00 AM

Following the United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance (AMR), Anatara Lifesciences (ASX:ANR) confirmed its commitment to fighting AMR, starting with the food chain. Anatara, which is developing therapeutics for gastrointestinal diseases in production animals and humans announced today it had submitted an application to register Detach(TM).

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) APVMA Submission Major Milestone Achieved

🕔10/4/2016 8:29:45 AM

Anatara Lifesciences (ASX:ANR) is pleased to announce that it has lodged its application for approval to register Detach(TM) with the Australian Pesticides and Veterinary Medicines Authority (APVMA). Detach(TM) is a natural, non-antibiotic alternative for the control of diarrhoea in piglets.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Successful Completion of Target Safety Study

🕔9/8/2016 8:27:28 AM

Anatara Lifesciences (ASX:ANR) is pleased to announce the successful completion of its pivotal Target Animal Safety (TAS) Study for DetachTM, the Company's lead product for the control of diarrhoea in piglets.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Appendix 4E and Financial Report

🕔8/30/2016 8:20:29 AM

Anatara Lifesciences Ltd (ASX:ANR) today released its Appendix 4E for the period ending 30th June 2016.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Appendix 4C - Quarterly

🕔7/22/2016 8:47:40 AM

Chairman & CEO, Dr Mel Bridges said, "We are extremely pleased to report a positive cash flow for the last quarter, reinforcing a strong balance sheet and cash position. Our cash position allows Anatara the flexibility to execute on moving both our animal and human applications forward to commercial launch," Dr Bridges added.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Investor Presentation and Update

🕔7/11/2016 9:49:57 AM

Anatara Lifesciences (ASX:ANR) releases its latest institutional roadshow presentation and market update. This week CEO & Chairman Dr Mel Bridges and Co-Founder and Chief Scientific Officer (CSO) Dr Tracey Mynott will be conducting a roadshow updating existing and potential new institutional investors and analysts.

Read Full Article

FINANCE VIDEO: Anatara Lifesciences Ltd (ASX:ANR) Executive Interview Series with Chief Scientific Officer Dr. Tracy Mynott

🕔6/30/2016 2:32:40 PM

Anatara Lifesciences Limited (ASX:ANR) Chief Scientific Officer, Dr. Tracy Mynott, speaks with Tom Piotrowski at CommSec's The Executive Series, by Commonwealth Bank Australia (ASX:CBA).

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Expands Executive Team

🕔6/27/2016 10:25:33 AM

Anatara Lifesciences (ASX:ANR) announces changes to its management team, including the retirement of Dr Paul Schober as CEO, transition of Dr Mel Bridges into a combined CEO / Chairman role as well as the appointment of Dr Mike West as COO and Ms Kylie Davis as Clinical Trials Manager.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Investor Presentation - Natural Alternative to Antibiotics

🕔6/23/2016 11:12:54 AM

Anatara Lifesciences (ASX:ANR) is pleased to release a copy of the presentation that Chairman, Dr Mel Bridges presented at the Finance News Network CEO Conference and the Gold Coast Investment Showcase this week.

Read Full Article

Biotech Investors Move Ahead on the Learning Curve

🕔6/11/2015 3:13:43 PM

Australian and New Zealand biotech investors are set to hear from a top line up of speakers from ASX-listed life science companies, as well as several private firms and international businesses, in July, at the 11th Bioshares Biotech Summit.

Read Full Article

News

Anatara Life Sciences (ASX:ANR) Investor Presentations Sydney and Melbourne

🕔2/11/2019 1:13:00 PM

This month, Anatara's CEO, Steve Lydeamore will be presenting to investors at events in Sydney and Melbourne. We would like to extend to you the invitation to attend.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Successful proof of concept studies

🕔2/7/2019 11:23:57 AM

Anatara Lifesciences Ltd (ASX:ANR) is pleased to report positive efficacy data from its in vitro Proof of Concept studies of its Gastrointestinal ReProgramming product. GaRP is a unique natural dietary supplement designed to restore and maintain a healthy human gut and microbiome.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Quarterly Report

🕔1/30/2019 11:03:48 AM

Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st December 2018. The Company's cash position at the end of the quarter stood at $1.5m. The Company also had $4,500,000 in deposits with terms of greater than 90 days. Expenditure during the quarter was in line with forecast.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Non-Executive Director Appointment

🕔1/23/2019 8:21:56 AM

Anatara Lifesciences (ASX:ANR) is pleased to announce the appointment of Dr. David Brookes as Non-Executive Director and Chair of the Audit and Risk Committee, effective from 23 January 2019.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) PAC Partners Equity Research Report

🕔1/15/2019 12:31:24 PM

PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a BUY rating and a 12-month price target of $1.40 per share.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Receives $1.249m R&D Tax Refund

🕔1/14/2019 8:39:28 AM

Anatara Lifesciences (ASX:ANR) is pleased to announce that it has received $1,249,299 from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive scheme.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Chairman's Address to Shareholders

🕔11/14/2018 10:20:11 AM

Anatara Lifesciences Ltd (ASX:ANR) provides the Company's Chairman Address to Shareholders.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Chief Executive Officer Appointment

🕔11/14/2018 8:23:04 AM

Anatara Lifesciences (ASX:ANR) is pleased to announce that it has appointed Mr Steven Lydeamore as Chief Executive Officer, effective as of 3rd December 2018.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Quarterly Report

🕔10/31/2018 10:01:44 AM

Anatara Lifesciences (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 30th September 2018. The Company's cash position at the end of the quarter stood at $7.1m.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) APVMA Approval for Detach

🕔10/29/2018 9:16:27 AM

Anatara Lifesciences (ASX:ANR) is pleased to announce that the Australian Pesticides and Veterinary Medicines Authority has registered Detach(R) with the approved label, "To aid in the control of scour and has positive health benefits in weaned piglets from 3 weeks of age and help increase survivability of scouring pre-weaning piglets".

Read Full Article
###

0 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 467) (Last 30 Days: 1409) (Since Published: 30772) 

Markets ASX:ANR

Company Data

    Headquarters
  • 433 Logan Road, Stones Corner
    Brisbane, Queensland 4120
    Australia
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.anataralifesciences.com
  • E:
  • info@anataralifesciences.com

Company Reports

Presentations

Research Report

Quarterly Report

Social Media